Divis Laboratories Ltd | DIVI - Selling And Administration Expenses


Divis Laboratories Ltd reported INR3.4B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Aurobindo Pharma INR 12.77B 485.3M Sep/2025
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
IQVIA Holdings USD 502M 34M Mar/2026
Lupin INR 11.06B 225.6M Sep/2025
Moderna USD 173M 135M Mar/2026
Organon & Co USD 433M 34M Dec/2025
Revvity USD 253.88M 2.15M Mar/2026
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025